AnaptysBio, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (11)

Latest Posts

About This Stock More About This Stock
AnaptysBio Price Target Raised To $145 From $101 At Jefferies
Article By: The Fly
Monday, February 19, 2018 2:20 PM EDT
Jefferies analyst Biren Amin raised his price target for AnaptysBio to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients.
In this article: ANAB Also: SNY, REGN
Read
5 Best Performing IPOs Of 2017
Article By: Zacks Investment Research
Friday, December 29, 2017 6:28 PM EDT
2017 marked a bounce back for the U.S. IPO market courtesy of improving economic fundamentals and consumer sentiment. Successful IPOs poured in primarily from the biotech and technology sectors and featured the comeback of Chinese issuers.
In this article: URGN, ANAB, SGH, CLXT, ROKU, SNAP, APRN
Read
4 Biotech Stocks Ready To Crush The Market In 2018
Article By: Zacks Investment Research
Wednesday, December 27, 2017 7:51 PM EDT
The year 2017 has been quite impressive one for the biotech sector as evident from the 19.4% gain registered so far by the Nasdaq Biotechnology Index. This is surely welcome news for investors since the industry suffered a decline of 19.2% last year.
In this article: SBMFF, ACAD, SGMO, ANAB Also: CELG, GILD
Read
Your IPO “Cheat Sheet” For June
Article By: Wall Street Daily
Monday, May 22, 2017 5:35 AM EDT
Are IPOs any type of indicator that can tell us a little bit about the underlying economy or the underlying stock market?
In this article: ANAB
Read
Cool Tech IPOs Finally Emerge After Drought
Article By: Jon Markman
Tuesday, February 21, 2017 2:17 PM EDT
It has become a cliché. If your business is not scarfing up new technology, it’s being devoured by it. Given the choice, companies are choosing to eat... with more than $3.6 trillion in deals announced,
In this article: CSCO, ANAB, JNCE, NTNX, TWLO, ACIA, PI
Read

PARTNER HEADLINES

Latest Tweets for $ANAB

No tweets yet!